71 124

Cited 4 times in

Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial

Authors
 Yeo-Eun Kim  ;  Bio Joo  ;  Mi-Suk Park  ;  Sang Joon Shin  ;  Joong Bae Ahn  ;  Myeong-Jin Kim 
Citation
 Cancer Research and Treatment, Vol.48(4) : 1210-1221, 2016 
Journal Title
 Cancer Research and Treatment 
ISSN
 1598-2998 
Issue Date
2016
MeSH
Adult ; Aged ; Bevacizumab/administration & dosage ; Biomarkers, Tumor/blood ; Colorectal Neoplasms/blood ; Colorectal Neoplasms/diagnostic imaging* ; Colorectal Neoplasms/drug therapy* ; Colorectal Neoplasms/pathology ; Contrast Media/administration & dosage ; Disease-Free Survival ; Female ; Humans ; Interleukin-8/blood ; Kaplan-Meier Estimate ; Liver Neoplasms/blood ; Liver Neoplasms/diagnostic imaging* ; Liver Neoplasms/drug therapy* ; Liver Neoplasms/secondary ; Magnetic Resonance Imaging* ; Male ; Middle Aged ; Placenta Growth Factor/blood ; Vascular Endothelial Growth Factor A/blood
Keywords
Bevacizumab ; Colorectal neoplasms ; Dynamic contrast enhanced-magnetic resonance imaging
Abstract
PURPOSE: The purpose of this study is to investigate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and plasma cytokines and angiogenic factors (CAFs) as pharmacodynamic and prognostic biomarkers of bevacizumab monotherapy in colorectal cancer with liver metastasis (CRCLM). MATERIALS AND METHODS: From July 2011 to March 2012, 28 patients with histologically confirmed CRCLM received bevacizumab monotherapy followed by combined FOLFOX therapy. The mean age of the patients was 57 years (range, 30 to 77 years). DCE-MRI (Ktransand IAUC60) was performed at baseline, first follow-up (3 days after bevacizumab monotherapy), and second follow-up (3 days after combined therapy). CAF levels (vascular endothelial growth factor [VEGF], placental growth factor [PlGF], and interleukin-8) were assessed on the same days. Progression-free survival (PFS) time distributions were summarized using the Kaplan-Meier method and compared using log-rank tests. RESULTS: The median PFS period was 11.2 months. Ktrans, IAUC60, VEGF, and PlGF values on the first follow-up day were significantly different compared with baseline values. No differences were observed on the second follow-up day. A > 40% decrease in Ktrans from baseline to first follow-up was associated with a longer PFS (hazard ratio, 0.349; 95% confidence interval, 0.133 to 0.912; p=0.032). Changes in CAFs did not show correlation with PFS time. CONCLUSION: DCE-MRI parameters and CAFs are pharmacodynamic biomarkers of bevacizumab for CRCLM. In our study, change in Ktrans at 3 days after bevacizumab monotherapy was a favorable prognostic factor; however, the value of CAFs as a prognostic biomarker was not found.
Files in This Item:
T201604435.pdf Download
DOI
10.4143/crt.2015.374
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Myeong Jin(김명진) ORCID logo https://orcid.org/0000-0001-7949-5402
Park, Mi-Suk(박미숙) ORCID logo https://orcid.org/0000-0001-5817-2444
Shin, Sang Joon(신상준) ORCID logo https://orcid.org/0000-0001-5350-7241
Ahn, Joong Bae(안중배) ORCID logo https://orcid.org/0000-0001-6787-1503
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/152461
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse